Effect of hyperchloremia on acute kidney injury in critically ill septic patients: a retrospective cohort study

Lenar Yessayan
Javier A. Neyra
Fabrizio Canepa-Escaro
George Vasquez-Rios
Michael Heung

See next page for additional authors

Follow this and additional works at: https://scholarlycommons.henryford.com/nephrology_articles

Recommended Citation
Yessayan L, Neyra JA, Canepa-Escaro F, Vasquez-Rios G, Heung M, and Yee J. Effect of hyperchloremia on acute kidney injury in critically ill septic patients: a retrospective cohort study. BMC Nephrol 2017; 18(1):346.
Authors
Lenar Yessayan, Javier A. Neyra, Fabrizio Canepa-Escaro, George Vasquez-Rios, Michael Heung, Jerry Yee, and Jerry Yee

This article is available at Henry Ford Health System Scholarly Commons: https://scholarlycommons.henryford.com/nephrology_articles/62
Effect of hyperchloremia on acute kidney injury in critically ill septic patients: a retrospective cohort study

Lenar Yessayan 1*, Javier A. Neyra 2,3, Fabrizio Canepa-Escar 4, George Vasquez-Rios 2, Michael Heung 1, Jerry Yee 5 and for the Acute Kidney Injury in Critical Illness Study Group

Abstract

Background: Hyperchloremia is common in critically ill septic patients. The impact of hyperchloremia on the incidence of acute kidney injury (AKI) is not well studied. We investigated the association between hyperchloremia and AKI within the first 72 h of intensive care unit (ICU) admission.

Methods: 6490 ICU adult patients admitted with severe sepsis or septic shock were screened for eligibility. Exclusion criteria included: AKI on admission, baseline estimated glomerular filtration rate (eGFR) <15 ml/min/1.73 m2, chronic renal replacement therapy, absent baseline serum creatinine data, and absent serum chloride data on ICU admission.

Results: A total of 1045 patients were available for analysis following the implementation of eligibility criteria: 303 (29%) had hyperchloremia (Cl ≤ 110 mEq/L) on ICU admission, 561 (54%) were normochloremic (Cl 101–109 mEq/L) and 181 (17%) were hypochloremic (Cl ≤ 100 mEq/L). AKI within the first 72 h of ICU stay was the dependent variable. Chloride on ICU admission (Cl0) and change in Cl by 72 h (ΔCl = Cl72 – Cl0) were the independent variables. The odds for AKI were not different in the hyperchloremic group when compared to the normochloremic group [adjusted odds ratio (OR) =0.80, 95% confidence interval [CI] (0.51–1.25); p = 0.33] after adjusting for demographics, comorbidities, baseline kidney function, drug exposure and critical illness indicators including cumulative fluid balance and base deficit. Furthermore, within the subgroup of patients with hyperchloremia on ICU admission, neither Cl0 nor ΔCl was associated with AKI or with moderate/severe AKI (KDIGO Stage ≥ 2).

Conclusions: Hyperchloremia occurs commonly among critically ill septic patients admitted to the ICU, but does not appear to be associated with an increased risk for AKI within the first 72 h of admission.

Keywords: Hyperchloremia, Sepsis, Acute kidney injury, Chloride load

Background

Chloride is the most abundant anion in the extracellular fluid and the second most important contributor to plasma tonicity [1]. It plays an essential role in many body functions including acid-base balance, muscular activity, osmosis, and immunomodulation [2]. The possibility of harm from hyperchloremia, particularly in the context of fluid resuscitation with chloride-liberal solutions, has recently garnered the research interest of the scientific community. Recent observational studies have shown increased mortality with chloride rich solutions, [3] chloride load, [4] and hyperchloremia [5, 6]. Animal and human experiments have also suggested that chloride-rich solutions may have a detrimental effect on renal function [7–11]. Proposed explanations of this association include renal vasoconstriction leading to reduction in renal cortical tissue perfusion and renal interstitial edema leading to intracapsular hypertension [7–9]. However, a recent large cluster randomized trial in a heterogeneous population of patients did not demonstrate a difference in the risk of acute kidney injury (AKI) or mortality among those who received buffered...
data within the first day of ICU admission. Cumulative fluid balance was calculated based on total fluid input minus output within the first 72 h of ICU stay. These data did not include pre-ICU fluid administration. Base deficit was calculated by subtracting the serum HCO₃⁻ measurement on ICU admission from the normal serum HCO₃⁻ value of 24 mEq/L. Subject-specific variables were obtained from EHRs. Comorbidities (e.g., diabetes, hypertension, and heart failure) were identified using ICD-9-CM codes, except for anemia that was defined as admission hematocrit <39% for men and <36% for women. Data pertaining to drug exposure, red blood cell transfusion, and mechanical ventilation were based on hospital billing codes for the indexed admission within the time frame of the study.

Study outcomes
The primary outcome measure was the occurrence of any AKI (KDIGO Stage ≥1), or moderate/severe AKI (KDIGO Stage ≥2) within the first 72 h of ICU stay and was adjudicated based on Kidney Disease Improving Global Outcomes consensus SCR-based criteria by comparing the highest SCR measured within the first 72 h of ICU admission and the reference SCR within 3 months before admission [16].

Statistical analysis
The study sample was divided into 3 subgroups based on serum chloride (Cl) levels at the time of ICU admission: hyperchloremia (Cl₀ ≥ 110 mEq/L), normochloremia (Cl₀ 101–109 mEq/L) and hypochloremia (Cl₀ ≤ 100 mEq/L). Categorical data were reported as percentages and continuous data as means ± standard deviation or median (25th – 75th percentile). For categorical variable comparison between the three subgroups, the chi-square test was used. Analysis of variance (ANOVA) was used for continuous variable comparisons when data were normally distributed and the Kruskal-Wallis test was used for non-normally distributed data.

The associations between AKI (any AKI or moderate/severe AKI) within 72 h (dependent variable) and 1) serum chloride subgroups on ICU admission and 2) admission serum chloride levels (Cl₀) within the hyperchloremic subgroup and 3) delta serum chloride at 72 h (ΔCl = Cl₁₀ – Cl₀) within the hyperchloremic subgroup were examined using multivariable logistic regression models. These associations were also tested within the hypochloremic subgroup. For the three chloride subgroup comparison in the incidence of AKI, a multivariable logistic regression model was used. The model was adjusted for confounders that were unequally distributed between the three subgroups (p-value for comparison <0.25 in Table 1). To further test whether worsening hyperchloremia is associated with AKI in the hyperchloremic
subgroup, we evaluated the association of serum chloride on ICU admission (Cl₀) and delta chloride (ΔCl = Cl₇₂ – Cl₀) with the incidence of AKI within 72 h in this subgroup. The multivariable logistic models included all variables with P-value of <0.25 in univariate models of AKI. Candidate variables included demographic data (age, gender, and race); comorbidity (baseline eGFR, diabetes, hypertension, heart failure, and anemia); indicators of critical illness (oliguria, APACHE II, SOFA, cumulative fluid balance, base deficit, mechanical ventilation, red blood cell transfusion); and drug exposure (diuretic, statin, aminoglycoside, and intravenous or intra-arterial iodine contrast). Only 1 of 2 variables was included in the event of collinearity between variables. The 95% CIs reported for the logistic regression odds ratios (ORs) were calculated by the Wald estimation. Two-sided P-values <0.05 indicated statistical significance. Spreadsheet software and SAS 9.3 (SAS Institute, Cary, NC) were used for data acquisition and analysis.

Results

Of 6490 patients examined for eligibility, 1045 satisfied inclusion and exclusion criteria (Fig. 1). Age was 66.0 ± 16.1 years, 360 (34.5%) were African Americans, 479 (45.8%) were male. A total of 482 (46.1%) patients were either on vasopressors or inotropes and 315 (30.1%) were on diuretics. The median cumulative fluid balance in the first 72 h of ICU stay was 2063 ml [25th – 75th percentile, –678 to 6029 ml]. The mean SOFA score was 4.9 ± 3.6 and APACHE II score was 12.9 ± 6.2. The mean

| Table 1 Clinical characteristics stratified by 3 serum chloride subgroups at the time of ICU admission: Hyperchloremia (Cl₀ ≥ 110 mEq/L); Normochloremia, (Cl₀ 100–109 mEq/L); and Hypochloremia (Cl₀ ≤ 100 mEq/L) |
|---------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Variable                        | Admission Serum Chloride (Cl₀) 110 mEq/L (n = 303) | Admission Serum Chloride (Cl₀) 100–109 mEq/L (n = 561) | Admission Serum Chloride (Cl₀) ≤100 mEq/L (n = 181) |
|---------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Demographics                    |                                                  |                                                  |                                                  |
| Age, years, mean ± SD           | 67.9 ± 15.6                                      | 64.8 ± 16.7                                      | 67.0 ± 14.6                                      |
| Male, %                         | 44.9%                                            | 53.7%                                            | 55.8%                                            |
| African-American, %             | 42.6%                                            | 33.2%                                            | 24.9%                                            |
| Chronic conditions              |                                                  |                                                  |                                                  |
| Baseline Scr, mg/dl, median (IQR)| 1.2 (0.9–1.7)                                    | 1.2 (0.9–1.6)                                    | 1.2 (0.9–1.6)                                    |
| Baseline eGFR, mL/min/1.73m², median (IQR) | 57.0 (40.4–76.8)                               | 63.1 (44.2–87.9)                                | 61.2 (42.1–88.0)                                |
| Diabetes, %                     | 23.8%                                            | 20.1%                                            | 21.6%                                            |
| Hypertension, %                 | 46.5%                                            | 46.5%                                            | 43.7%                                            |
| Heart failure, %                | 3.3%                                             | 2.1%                                             | 4.4%                                             |
| Anemia, %                       | 88.6%                                            | 85.1%                                            | 74.4%                                            |
| Drug Exposure                   |                                                  |                                                  |                                                  |
| Diuretic, %                     | 44.2%                                            | 44.0%                                            | 55.8%                                            |
| Statin, %                       | 28.7%                                            | 30.8%                                            | 30.4%                                            |
| Iodine contrast, %              | 27.7%                                            | 33.9%                                            | 29.3%                                            |
| Aminoglycoside, %               | 8.3%                                             | 6.1%                                             | 1.7%                                             |
| Critical indicators             |                                                  |                                                  |                                                  |
| Oliguria, %                     | 9.0%                                             | 6.2%                                             | 5.3%                                             |
| CFB 72 h, liters, median (IQR)  | 3.1 (–0.1–8.0)                                   | 2.0 (–0.5–5.4)                                   | 0.75 (–2.1–3.8)                                  |
| Pressor or inotrope, %          | 37.3%                                            | 30.1%                                            | 27.6%                                            |
| Mechanical ventilation, %       | 51.2%                                            | 39.4%                                            | 33.2%                                            |
| Red blood cell transfusion, %   | 6.6%                                             | 2.0%                                             | 0.6%                                             |
| Base Deficit, mmol/L Median (IQR)| 3.6 (1.7–6.4)                                   | 1.1 (–1.7–4.0)                                  | –2.6 (–7.4–2.4)                                  |
| APACHE II score, mean ± SD      | 14.9 ± 7.0                                       | 12.1 ± 5.9                                       | 11.80 ± 5.06*                                   |
| SOFA score, mean ± SD           | 5.8 ± 3.8                                        | 4.5 ± 3.4                                        | 4.4 ± 3.4*                                       |

*eGFR = estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) Study equation; Scr = serum creatinine; iodine contrast only if intravenous or intra-arterial; CFB = cumulative fluid balance; oliguria defined as urine output less than 500 ml in 24 h; anemia = admission hematocrit <39% for men and <36% for women; APACHE II = Acute Physiology and Chronic Health Evaluation II; SOFA = Sequential Organ Failure Assessment
base deficit was 1.9 ± 7.0 mEq/L. Serum chloride on ICU admission was 106 ± 7 mEq/L (range 82 – 130 mEq/L) and 237 (22.7%) of patients developed AKI within the first 72 h of ICU stay.

Of the 1045 patients that satisfied eligibility criteria, 303 (29.0%) were hyperchloremic (Cl₀ ≥ 110 mEq/L) on ICU admission, 561 (53.7%) were normochloremic (Cl₀ 101–109 mEq/L) and 181 (17.3%) were hypochloremic (Cl₀ ≤ 100 mEq/L). Baseline characteristics by admission chloride subgroup are shown in Table 1. The following variables were unequally distributed between the three serum chloride subgroups: age, gender, race, anemia, heart failure, aminoglycoside use, diuretic administration, intravenous or intra-arterial iodine exposure, pressor or inotrope use, cumulative fluid balance, % weight gain, mechanical ventilation, red blood cell transfusion, base deficit, oliguria and indices of critical illness severity (APACHE II and SOFA scores). A multivariable logistic regression model adjusted for the aforementioned variables did not show any difference in the odds for any AKI in the hyperchloremic group when compared to the normochloremic group [adjusted odds ratio = 0.80, 95% confidence interval [CI] (0.51–1.25); p = 0.33] and lower odds for AKI when compared to the hypochloremic group [adjusted OR = 0.50, 95% CI (0.28–0.91); p = 0.03]. The odds for moderate/severe AKI in the hyperchloremic group were not different from the normochloremic group [adjusted odds ratio = 0.97, 95% CI (0.50–1.91); p = 0.93] or the hypochloremic group [adjusted OR = 0.42, 95% CI (0.18–1.01); p = 0.05].

The independent association of both serum chloride levels on admission (Cl₀) and delta chloride (ΔCl) with AKI at 72 h was assessed in multivariable models within the hyperchloremic subgroup. All variables with P values of <0.25 from the univariate analyses were included in the multivariate analyses. Serum chloride level on admission (Cl₀) was not associated with the occurrence of AKI at 72 h [adjusted odds ratio per 1 mEq/L increase in Cl₀ = 0.99, 95% CI (0.89–1.09); p = 0.81] or moderate/severe AKI at 72 h [adjusted odds ratio per 1 mEq/L increase in Cl₀ = 0.95, 95% CI (0.81–1.11); p = 0.52] (Table 2). Furthermore, within-subject change in serum chloride (ΔCl) during the first 72 h of ICU stay was also not associated with either AKI at 72 h [adjusted odds ratio per 1 mEq/L increase in ΔCl =1.04, 95% CI (0.97–1.11); p = 0.27] or moderate/severe AKI at 72 h [adjusted odds ratio per 1 mEq/L increase in ΔCl =1.03, 95% CI (0.93–1.14); p = 0.62] (Table 3).

In the hypochloremic subgroup, and using the same multivariable models, there was no independent association between the occurrence of AKI at 72 h and either serum chloride levels on admission (Cl₀) [adjusted odds ratio per 1 mEq/L decrease in Cl₀ = 1.02, 95% CI (0.91–1.15); p = 0.67] or delta chloride (ΔCl) [adjusted odds ratio per 1 mEq/L decrease in ΔCl =1.18, 95% CI (0.41–3.40); p = 0.66].

**Discussion**

In this large retrospective cohort study of critically ill septic patients, we did not find an association between
Table 2 Univariable analyses of determinants of any AKI and multivariable analyses investigating the association between chloride levels on ICU admission and 1) any AKI at 72 h and 2) moderate/severe AKI at 72 h

| Variable                  | Any AKI | Any AKI | Moderate/Severe AKI |
|---------------------------|---------|---------|---------------------|
|                           | Odds Ratio | P-value | Odds Ratio | P-value | Odds Ratio | P-value |
|                           | Univariable |         | Multivariable |         | Multivariable |         |
| Cl0 per mEq/L increase    | 1.01 (0.94–1.09) | 0.7317 | 0.99 (0.89–1.09) | 0.8072 | 0.95 (0.81–1.11) | 0.5200 |
| Age, years                | 1.00 (0.98–1.01) | – | – | – | – | – |
| Male                      | 1.65 (0.95–2.87) | 0.0774 | 1.72 (0.80–3.69) | 0.1625 | 3.03 (0.89–10.29) | 0.0750 |
| African-American          | 1.25 (0.72–2.17) | 0.4338 | – | – | – | – |
| Baseline eGFR per mL/min/1.73m^2 | 1.00 (0.99–1.01) | 0.9957 | – | – | – | – |
| Diabetes                  | 0.61 (0.30–1.23) | 0.1672 | 0.54 (0.22–1.35) | 0.1874 | 0.75 (0.22–2.61) | 0.6514 |
| Hypertension              | 0.63 (0.36–1.10) | 0.1045 | 0.75 (0.37–1.54) | 0.4370 | 1.02 (0.36–2.93) | 0.9655 |
| Heart failure             | 3.97 (1.11–14.15) | 0.0338 | 3.86 (0.93–16.06) | 0.0633 | 1.90 (0.22–16.62) | 0.5640 |
| Anemia                    | 1.26 (0.50–3.18) | 0.6305 | – | – | – | – |
| Diuretic                  | 2.37 (1.34–4.16) | 0.0028 | 2.63 (1.21–5.74) | 0.0150 | 1.75 (0.56–5.45) | 0.3362 |
| Statin                    | 0.64 (0.33–1.22) | 0.1760 | 0.47 (0.21–1.07) | 0.0728 | 1.00 (0.31–3.22) | 0.9996 |
| Iodine contrast           | 1.24 (0.68–2.27) | 0.4783 | – | – | – | – |
| Aminoglycoside            | 1.20 (0.46–3.14) | 0.7131 | – | – | – | – |
| Oliguria                  | 5.35 (2.25–12.72) | 0.0002 | 3.54 (1.20–10.46) | 0.0223 | 10.77 (2.84–40.85) | 0.0005 |
| CFB 72 h per 100 ml increase | 1.00 (1.00–1.02) | 0.0342 | 1.00 (1.00–1.01) | 0.1772 | 1.05 (1.00–1.01) | 0.0910 |
| Pressor or inotrope       | 2.49 (1.42–4.37) | 0.0014 | 1.28 (0.53–3.05) | 0.5839 | 1.77 (0.45–6.87) | 0.4122 |
| Mechanical ventilation    | 1.96 (1.11–3.46) | 0.0212 | 0.84 (0.34–2.03) | 0.6944 | 0.72 (0.19–2.76) | 0.6359 |
| Red blood cell transfusion | 0.64 (0.18–2.26) | 0.4908 | – | – | – | – |
| Base Deficit per mEq/L increase | 1.03 (0.98–1.09) | 0.2254 | 1.06 | 0.1211 | 1.10 (1.00–1.20) | 0.0512 |
| APACHE II score, per unit increase | 1.05 (1.01–1.09) | 0.0231 | – | – | – | – |
| SOFA score per unit increase | 1.19 (1.11–1.29) | <0.0001 | 1.12 (0.99–1.27) | 0.0772 | 1.06 (0.88–1.27) | 0.5502 |

* eGFR = estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) Study equation; SCr = serum creatinine; iodine contrast only if intravenous or intra-arterial; CFB = cumulative fluid balance; oliguria defined as urine output less than 500 ml in 24 h; anemia = admission hematocrit <39% for men and <36% for women; APACHE II = Acute Physiology and Chronic Health Evaluation II; SOFA = Sequential Organ Failure Assessment. Any AKI, KDIGO Stage ≥1 SCr-based; Moderate/severe AKI, KDIGO Stage ≥2 SCr-based.

The univariate logistic regression analyses are investigating 20 variables as potential predictors of AKI. The two multivariate models are investigating the association between chloride levels on admission (Cl0) and 1) any AKI at 72 h and 2) moderate/severe AKI at 72 h in the hyperchloremic subgroup. Both models are adjusted for variables with P-value < 0.25 on univariate analysis. Variables included for confounding adjustment in the final model are gender, diabetes, hypertension, heart failure, diuretics, statins, oliguria, cumulative fluid balance, pressor or inotrope, mechanical ventilation, base deficit and Sequential Organ Failure Assessment (SOFA) score. Acute Physiology and Chronic Health Evaluation II (APACHE II) was not included in the final multivariable model because of collinearity with SOFA score.
admission hyperchloremia (Cl0 ≥ 110 mEq/L) and AKI within 72 h of ICU stay. We also could not detect an association between higher serum chloride levels on admission or worsening serum chloride levels in the first 72 h and AKI among those patients with hyperchloremia at the time of ICU admission. The latter finding further supports the absence of any appreciable detrimental effect of hyperchloremia on kidney function in patients with severe sepsis or septic shock.

Hyperchloremia is prevalent in the ICU, afflicting nearly up to a third of the ICU population in some reports [6, 17]. Over the past few years there has been an increasing focus on the potential impact of chloride load in resuscitation fluid and serum chloride on outcomes in critically ill patients. Several large observational studies have associated chloride-rich crystalloid solutions, chloride load and hyperchloremia with increased hospital mortality and/or with AKI [3–6, 10, 11, 17, 18].

In a large retrospective study, Sen et al. found an association between total chloride load and all-cause mortality in 4710 critically ill non-surgical patients who received at least 60 mL/kg fluid resuscitation within a 24 h period [18]. However, this association did not persist after adjusting for age, volume of administered fluid and baseline severity of illness. Shaw et al. conducted a retrospective study to examine the effect of chloride load among 109,836 patients with systemic inflammatory response and demonstrated an association between higher intravenous chloride loads and hospital mortality [4]. Raghunathan et al. examined non-surgical critically ill patients with sepsis and, using propensity-matching (n = 6730), reported an association between the use of chloride-rich solutions and increased risk for hospital mortality but not AKI [3]. We previously showed an association between worsening hyperchloremia and hospital mortality in critically ill septic patients admitted with hyperchloremia [6]. Similarly, a single center

| Variable                     | Any AKI Hyperchloremic Subgroup | Moderate/Severe AKI Hyperchloremic Subgroup |
|------------------------------|---------------------------------|---------------------------------------------|
| **ΔCl** by mEq/L increase    | 1.04 (0.97–1.11)                | 1.03 (0.93–1.14)                            |
| Male                         | 1.49 (0.60–3.70)                | 6.38 (1.16–34.99)                           |
| Diabetes                     | 0.55 (0.20–1.50)                | 0.88 (0.21–3.73)                            |
| Hypertension                 | 0.60 (0.26–1.36)                | 0.55 (0.15–1.95)                            |
| Heart failure                | 7.06 (1.33–37.52)               | 2.54 (0.15–43.62)                           |
| Diuretic                     | 3.35 (1.26–8.91)                | 3.61 (0.74–17.60)                           |
| Statin                       | 0.51 (0.20–1.30)                | 1.12 (0.26–4.83)                            |
| Oliguria                     | 6.09 (1.66–22.39)               | 33.05 (4.89–223.45)                         |
| CFB 72 h by 100 ml increase  | 1.00 (1.00–1.01)                | 1.01 (1.00–1.02)                            |
| Pressor or inotrope          | 1.37 (0.51–3.69)                | 1.66 (0.35–8.01)                            |
| Mechanical ventilation       | 1.10 (0.36–3.32)                | 1.46 (0.26–8.37)                            |
| Base Deficit by mEq/L increase | 1.05 (0.96–1.15)            | 1.12 (0.96–1.30)                            |
| SOFA score by unit increase  | 1.09 (0.95–1.25)                | 0.98 (0.80–1.20)                            |

CFB = cumulative fluid balance; oliguria defined as urine output less than 500 ml in 24 h; anemia = admission hematocrit <39% for men and <36% for women; SOFA = Sequential Organ Failure Assessment; Any AKI, KDIGO Stage ≥1 Scr-based; Moderate/severe AKI, KDIGO Stage ≥2 Scr-based

The two multivariate models are investigating the association between delta chloride at 72 h (ΔCl = Cl72 − Cl0) and 1) any AKI at 72 h and 2) moderate/severe AKI at 72 h in the hyperchloremic subgroup. Both models are adjusted for variables with P-value <0.25 on univariate analysis reported in Table 2

Yessayan et al. BMC Nephrology (2017) 18:346 Page 6 of 9
prospective study by Boniatti et al. showed that hyperchloremia was associated with hospital mortality. Although serum chloride was not a good predictor of hospital mortality, a clinical model that included albumin, age, SOFA score, in addition to serum chloride provided a good discriminatory ability to predict mortality (area under the receiver operating curve for this model was 0.80 [95% confidence interval, 0.73–0.87]) [5]. Zhang et al. showed that patients with AKI have higher maximum chloride levels than patients who did not develop AKI in a group of medical, surgical and post-cardiac surgery patients. A distinctive difference with our study is that they did not adjust for disease severity scores such as SOFA or APACHE-II, and the serum chloride levels (predictor) were not examined at contemporaneous time points in reference to the occurrence of AKI [11]. We selected AKI within 72 h of ICU admission as the main outcome of our study to adjust for critical clinical parameters during this time period (i.e., SOFA score and cumulative fluid balance) that may confound the relationship between serum chloride levels and AKI.

Proposed explanations of renal damage by chloride-rich solutions include dysregulated tubuloglomerular feedback activated by chloride reaching the macula densa and causing renal afferent arteriole vasoconstriction leading to a reduction in renal cortical tissue perfusion and consequent tissue ischemia. An alternative mechanism is through fluid overload and renal interstitial edema leading to intracapsular hypertension or vaso-motor nephropathy [7, 9, 19].

Observational studies have shown an association between chloride-rich solutions and AKI. Yunus and colleagues, in a large prospective study of quasi-experimental design (1533 patients), reported a lower incidence of AKI when a chloride-restrictive fluid strategy was implemented in the ICU (8.4% versus 14.0%, \( p < 0.001 \)) [10]. A distinctive difference with our study is that they did not adjust for disease severity scores such as SOFA or APACHE-II, and the serum chloride levels (predictor) were not examined at contemporaneous time points in reference to the occurrence of AKI [11]. We selected AKI within 72 h of ICU admission as the main outcome of our study to adjust for critical clinical parameters during this time period (i.e., SOFA score and cumulative fluid balance) that may confound the relationship between serum chloride levels and AKI. A recent meta-analysis of 21 studies (6253 patients) found that administration of chloride-rich fluids was associated with increased risk for hyperchloremic acidosis and AKI but not mortality [20].

The association of chloride-rich solutions with AKI was not observed in two recent controlled trials. The SPLIT trial, a major trial of buffered crystalloids versus 0.9% saline among 2278 ICU patients, found no difference in the incidence of AKI or rates of renal replacement therapy between the two strategies [12]. Similarly, the LICRA pragmatic trial, a study comparing perioperative chloride-poor intravenous fluids to chloride-rich intravenous fluids among 1136 patients, did not show a difference in the incidence of AKI after adult cardiothoracic surgery [21].

Conclusions
In conclusion, our study did not show an association between hyperchloremia and the incidence of AKI within the first 72 h of ICU stay in critically ill septic patients. It is conceivable that the administration of chloride rich
solutions itself, rather than any resulting hyperchloremia, is what confers the risk of AKI. It is also plausible that there is no causal relationship between hyperchloremia or exposure to high chloride solutions and AKI in this population. In the absence of clinical trials showing definitive evidence of lack of harm with higher chloride loads, it is probably prudent to minimize chloride load when large amounts of crystalloids have already been administered or when patients are already hyperchloremic. Future randomized control trials evaluating the effect of buffered solutions on AKI should include data pertaining to serum chloride levels during the study period.

Abbreviations
AKI: Acute kidney injury; APACHE II: Acute Physiology and Chronic Health Evaluation II; CFB: Cumulative fluid balance; eGFR: estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) Study equation; EHR: Electronic health record; ICD-9-CM: International Classification of Diseases, Ninth Revision, Clinical Modification Codes; ICU: Intensive care unit; KDIGO: Kidney Disease Improving Global Outcomes; OR: Odds ratio; Scr: Serum creatinine; SOFA: Sequential Organ Failure Assessment.

Acknowledgements
None.

Funding
Research reported in this publication was supported by the Division of Nephrology and Hypertension of Henry Ford Hospital.

Availability of data and materials
Data will not be shared.

Authors’ contributions
LY, JAN, FC, JY contributed to the study concept and design. JAN, FC, JY acquired the data. LY and JY analysed the data. All authors revised the manuscript for important intellectual content. All authors read and approved the final manuscript.

Ethics approval and consent to participate
We conducted a single-center, retrospective cohort study utilizing a population-based, ICU database of adult patients with severe sepsis or septic shock admitted to Henry Ford Hospital. Data were electronically extracted from electronic health record (EHR) by data management personnel blinded to the study. The protocol was approved by the institutional review board of Henry Ford Hospital (IRB #7044).

Consent for publication
Not applicable.

Competing interests
LY was employed by Henry Ford Health System during the course of the study. He is currently employed by the University of Michigan. The authors declare that they have no relevant financial interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Nephrology, University of Michigan, 3914 Taubman Center, 1500 E. Medical Center Dr. 5364, Ann Arbor, MI 48109-5364, USA. 2Division of Nephrology, Bone and Mineral Metabolism, University of Kentucky Medical Center, Lexington, KY, USA. 3Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern, Dallas, TX, USA. 4Division of Hospitalist Medicine, University of Kentucky Medical Center, Lexington, KY, USA. 5Division of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI, USA.

Received: 5 June 2017 Accepted: 13 November 2017 Published online: 02 December 2017

References
1. Half JE, Guyton AC, Guyton and hall textbook of medical physiology. 12th ed. Philadelphia: Saunders/Elsevier; 2011.
2. Berend K, van Hulteijn LH, Gans RO. Chloride: the queen of electrolytes? European journal of internal medicine. 2012;23(3):203–11.
3. Raghunathan K, Shaw A, Nathanson B, Strumler T, Brookhart A, Stefan MS, Setoguchi S, Beadles C, Lindenauer PK. Association between the choice of IV crystalloid and in-hospital mortality among critically ill adults with sepsis. Crit Care Med. 2014;42(7):1585–91.
4. Shaw AO, Raghunathan K, Peyerl FW, Munson SH, Paluszewicz SM, Schermer CR. Association between intravenous chloride load during resuscitation and in-hospital mortality among patients with SIRS. Intensive Care Med. 2014;40(12):1897–905.
5. Boniatti MM, Cardoso PR, Castillo RK, Vieira SR. Is hyperchloremia associated with mortality in critically ill patients? A prospective cohort study. J Crit Care. 2011;26(2):175–9.
6. Neyra JA, Canepa-Escaro F, Li X, Manlio J, Adams-Huet B, Yee J, Yessayan L. Association of Hyperchloremia with Hospital Mortality in Critically Ill septic patients. Crit Care Med. 2015;43(9):1938–44.
7. Wilcox CS. Regulation of renal blood flow by plasma chloride. J Clin Invest. 1985;73(3):226–35.
8. Wauters J, C茨u P, Brosens N, McLaughlin M, Malbrain M, Wilmer A. Pathophysiology of renal hemodynamics and renal cortical microcirculation in a porcine model of elevated intra-abdominal pressure. J Trauma. 2009;66(3):713–9.
9. Stone HH, Fulenwider JT. Renal decapsulation in the prevention of post-ischemic oliguria. Ann Surg. 1977;186(3):343–55.
10. Yunos NM, Bellomo R, Hegazy C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012;308(15):1566–72.
11. Zhang Z, Xu X, Fan H, Li D, Deng H. Higher serum chloride concentrations are associated with acute kidney injury in unselected critically ill patients. BMC Nephrol. 2013;14(1):1–6.
12. Young P, Bailey M, Beasley R, et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: the split randomized clinical trial. JAMA. 2015;314(16):1701–10.
13. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Cacillo J, Pinksy MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–10.
14. Waikar SS, Wald R, Chertow GM, Cuchar GC, Winkelmayer WC, Liangos O, Sosa MA, Jaber BL. Validity of international classification of diseases, ninth revision, clinical modification codes for acute renal failure. J Am Soc Nephrol. 2006;17(6):1588–94.
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate equation to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130(6):461–70.
16. Kellum JA, Lameire N, Group KAWG. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care. 2013;17(11):204.
17. Shao M, Li G, Sarvottam K, Wang S, Thongpryaoon C, Dong Y, Gajic O, Kashani K. Dyschloremia is a risk factor for the development of acute kidney injury in critically ill patients. PLoS One. 2016;11(8):e0160322.
18. Sen A, Keener CM, Sileo AE, Foldes E, Clermont G, Murugan R, Kellum JA. Chloride content of fluids used for large-volume resuscitation is associated with reduced survival. Crit Care Med. 2016.
19. Chowdhury AH, Cox EF, Francis ST, Lobo DNA. A randomized, controlled, double-blind crossover study on the effects of 2-L infusions of 0.9% saline and plasma-lyte® 148 on renal blood flow velocity and renal cortical tissue perfusion in healthy volunteers. Ann Surg. 2012;256.
20. Krajewski ML, Raghunathan K, Paluszewicz SM, Schermer CR, Shaw AD. Meta-analysis of high-versus low-chloride content in perioperative and critical care fluid resuscitation. Br J Surg. 2015;102(12):34–6.
21. McFray D, Murphy D, Kasza J, Bhadra D, Wutzlerfor H, Marasco S. Effects of restricting perioperative use of intravenous chloride on kidney injury in patients undergoing cardiac surgery: the LICRA pragmatic controlled clinical trial. Intensive Care Med. 2017.
22. Kellum JA, Song M, Almasri E. Hyperchloremic acidosis increases circulating inflammatory molecules in experimental sepsis. Chest. 2006;130(4):962–7.
23. Martin G, Bennett-Guerrero E, Wakeling H, Mythen MG, El-Moalem H, Robertson K, Kucmeroski D, Gan TJ. A prospective, randomized comparison of thromboelastographic coagulation profile in patients receiving lactated Ringer's solution, 6% hetastarch in a balanced-saline vehicle, or 6% hetastarch in saline during major surgery. J Cardiothorac Vasc Anesth. 2002; 16(4):441–6.